Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Account Payables (2016 - 2025)

OptimizeRx's Change in Account Payables history spans 16 years, with the latest figure at $55000.0 for Q3 2025.

  • For Q3 2025, Change in Account Payables rose 124.44% year-over-year to $55000.0; the TTM value through Sep 2025 reached -$718000.0, down 1187.88%, while the annual FY2024 figure was -$72000.0, 94.55% up from the prior year.
  • Change in Account Payables for Q3 2025 was $55000.0 at OptimizeRx, up from -$1.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.3 million in Q2 2024 and bottomed at -$1.4 million in Q2 2025.
  • The 5-year median for Change in Account Payables is -$118971.0 (2021), against an average of -$30487.9.
  • The largest annual shift saw Change in Account Payables soared 1074.64% in 2022 before it tumbled 4193.47% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at -$164837.0 in 2021, then skyrocketed by 433.27% to $549354.0 in 2022, then tumbled by 183.92% to -$461000.0 in 2023, then fell by 29.93% to -$599000.0 in 2024, then surged by 109.18% to $55000.0 in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Change in Account Payables are $55000.0 (Q3 2025), -$1.4 million (Q2 2025), and $1.2 million (Q1 2025).